Skip to main content
SpringerLink
Log in

PET/CT Imaging in Cardiac Sarcoidosis

  • Cardiac Nuclear Imaging (A Cuocolo, Section Editor)
  • Published:
Current Cardiovascular Imaging Reports Aims and scope Submit manuscript

Abstract

Cardiac sarcoidosis (CS) is a potentially life-threatening disease, but diagnosing CS remains a challenge because of nonspecific clinical manifestations and significant proportion of asymptomatic patients. Also, there is no standardized work-up for early diagnosis and management of CS. In recent years, there has been increasing interest in the use of advanced imaging modalities for evaluation of CS, including cardiac magnetic resonance imaging (MRI) and positron emission tomography with 18f-fluorodeoxyglucose (FDG PET) integrated with computed tomography (PET/CT). The purpose of this review is to highlight the utility of PET/CT for diagnosis and management of CS. The advantage of PET/CT is that it can detect FDG accumulation in the activated inflammatory cells, allowing visualization of active sites and early diagnosis of CS. Special emphasis has been put toward the development of appropriate preparation protocols that minimize physiological FDG uptake in the myocardium and optimal imaging protocols that allow sensitive and accurate detection of CS. Aside from early diagnosis, FDG PET/CT may inform when to start the therapy and whether the patient responded to treatment. FDG PET/CT may also be useful for follow-up and risk assessment of patients with CS. The limitations of FDG PET/CT are discussed with respect to a radiation exposure and control of glucose metabolism and insulin levels to avoid nonspecific myocardial uptake of FDG. Despite the progress made, more studies are needed to further refine clinical applications of FDG PET/CT in patients with CS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–65.

    Article  CAS  PubMed  Google Scholar 

  2. Morgenthau AS, Iannuzzii MC. Recent advances in sarcoidosis. Chest. 2011;139:174–82.

    Article  PubMed  Google Scholar 

  3. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183:573–81.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Judson MA. The diagnosis of sarcoidosis. Clin Chest Med. 2008;29:415–27.

    Article  PubMed  Google Scholar 

  5. Criado E, Sanchez M, Ramirez J, et al. Pulmonary sarcoidosis: typical and atypical manifestations at high resolution CT with pathological correlation. Radio Graph. 2010;30:1567–86.

    Google Scholar 

  6. Vardhanabhuti V, Venkatanarasimha N, Bhathagar G, et al. Extra-pulmonary manifestation of sarcoidosis. Clin Radiol. 2012;67:263–76.

    Article  CAS  PubMed  Google Scholar 

  7. Cox CE, Davis-Allen A, Judson MA. Sarcoidosis. Med Clin North Am. 2005;89:817–28.

    Article  PubMed  Google Scholar 

  8. Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006;92:282–8.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Keijsers RGM, van den Heuvel DAF, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J. 2013;41:743–51.

    Article  CAS  PubMed  Google Scholar 

  10. Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, et al. The utility of 18 F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012;53:1543–9.

    Article  PubMed  Google Scholar 

  11. Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, et al. Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis. Clin Nucl Med. 2013;38:516–21.

    Article  PubMed  Google Scholar 

  12. Mostard RLM, Voo S, van Kroonenburgh MJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med. 2011;105:1917–24.

    Article  CAS  PubMed  Google Scholar 

  13. Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132:1949–53.

    Article  PubMed  Google Scholar 

  14. Mostard RLM, Varschakelen JA, van Kroonenburgh MJ, et al. Severity of pulmonary involvement and 18 F-FDG PET activity in sarcoidosis. Respir Med. 2013;107:439–47.

    Article  PubMed  Google Scholar 

  15. Ambrosini V, Zompatori M, Fasano L, et al. 18 F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis. Results of preliminary prospective study. Clin Nucl Med. 2013;38:e171–7.

    Article  PubMed  Google Scholar 

  16. Mostard RL, Prompers L, Weijers RE, et al. F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl Med. 2012;37:21–5.

    Article  PubMed  Google Scholar 

  17. Jain V, Hasselquist S, Delaney M. PET scanning in sarcoidosis. Ann NY Acad Sci. 2011;1228:46–58.

    Article  PubMed  Google Scholar 

  18. Sobic-Saranovic D, Artiko V, Obradovic V. FDG PET Imaging in Sarcoidosis. Semin Nucl Med. 2013;43:404–11.

    Article  PubMed  Google Scholar 

  19. Treglia G, Annunziata S, Sobic-Saranovic D, et al. The role of 18 F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based reviewed. Acad Radiol. 2014;21:675–84.

    Article  PubMed  Google Scholar 

  20. Mochizuk T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42:1551–5.

    Google Scholar 

  21. Perry A, Vuitch F. Causes of death in patients with sarcoidosis: a morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119:167–72.

    CAS  PubMed  Google Scholar 

  22. Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study on fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976;278:455–69.

    Article  CAS  PubMed  Google Scholar 

  23. Tachibana T, Iwai K, Takemura T. Study on cause of death in the patients with sarcoidosis in Japan. Vasc Diffuse Lung Dis. 1992;9:307.

    Google Scholar 

  24. Gideon NM, Mannino DM. Sarcoidosis mortality in the United States, 1979-1991: an analysis of multi-cause mortality data. Am J Med. 1996;100:423–7.

    Article  CAS  PubMed  Google Scholar 

  25. Sharma OP, Masheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993;103:253–8.

    Article  CAS  PubMed  Google Scholar 

  26. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969–77.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Tavora F, Cresswell N, Li L, et al. Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. Am J Cardiol. 2009;104:571–7.

    Article  PubMed  Google Scholar 

  28. Roberts WC, McAllister HA, Ferrans VJ. Sarcoidosis of the heart: clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med. 1977;63:86–108.

    Article  CAS  PubMed  Google Scholar 

  29. Youssef G, Beanlands RS, Birnie DH, et al. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart. 2011;97:2078–87.

    Article  PubMed  Google Scholar 

  30. Banba K, Kusano KF, Nakamura K, et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm. 2007;4:1292–9.

    Article  PubMed  Google Scholar 

  31. Sekhri V, Sanal S, Delorenzo LJ, et al. Cardiac sarcoidosis: a comprehensive review. Arch Med Sci. 2011;7:546–54.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Hiraga H, Hiroe M, Iwai K, et al. Guideline for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases. (in Japanese). Tokyo, Japan:The Jpn Minist Health Welf. 1993:23–4.

  33. Diagnostic Standard and guidelines for sarcoidosis. Jpn J Sarcoidosis and Granulomatous Diseases. 2007:27:89–102.

  34. Ratner SJ, Fenoglio Jr JJ, Ursell PC. Utility of endomyocardial biopsy in the diagnosis of cardiac sarcoidosis. Chest. 1986;90:528–33.

    Article  CAS  PubMed  Google Scholar 

  35. Kaneta T, Hakamatsuka T, Takanami K, et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period and hospitalization. Ann Nucl Med. 2006;20:203–8.

    Article  PubMed  Google Scholar 

  36. Choi Y, Brunken RC, Hawkins RA, et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med. 1993;20:308–18.

    Article  CAS  PubMed  Google Scholar 

  37. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med. 2003;44:1030–6.

    PubMed  Google Scholar 

  38. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18 F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989–98.

    PubMed  Google Scholar 

  39. Ohira H, Tsujino I, Ishimura S, et al. Myocardial imaging with 18 F-fluoro-2-deoxygluoce positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933–41.

    Article  PubMed  Google Scholar 

  40. Langah R, Spicer K, Gebregziabher M, et al. Effectiveness of prolonged fasting 18 F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009;16:801–10.

    Article  PubMed  Google Scholar 

  41. Lum DP, Wandell S, Ko J, et al. Reduction of myocardial 2-deoxy-2-[18 F] fluoro-d-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol. 2002;4:232–7.

    Article  PubMed  Google Scholar 

  42. Williams G, Kolodny GM. Suppression of myocardial 18 F-FDG uptake by preparing patients with high-fat low-carbohydrate diet. Am J Roentgenol. 2008;190:W151–6.

    Article  Google Scholar 

  43. Soussan M, Brillet PY, Nunes H, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol. 2013;20:120–7.

    Article  PubMed  Google Scholar 

  44. Cheng VY, Slomka PJ, Ahlen M, et al. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18 F-FDG uptake during PET: a randomized controlled trial. J Nucl Cardiol. 2010;17:286–91.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18 F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26:1538–43.

    Article  PubMed  Google Scholar 

  46. Persson E. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragments (Fragmin). Acta Med Scand Suppl. 1988;724:1–56.

    Article  CAS  PubMed  Google Scholar 

  47. Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial 18 F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Research. 2014;4:1http://www.ejnmmires.com/content/4/1/1.

  48. Ohira H, Tsujino I, Yoshinaga K. 18F-fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2011;38:1773–83. This is an excellent review of patient preparation and imaging protocols.

    Article  CAS  PubMed  Google Scholar 

  49. Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC Imaging guidelines for nuclear cardiology procedures: PET myocardial perfusion and metabolism clinical imaging. J Nucl Cardiol 2009. Available at: https://www.asnc.org/imageuploads/ImagingGuidelinesPETJuly2009.pdf.

  50. Egashira T, Makino S, Kunitomi A, et al. Necessity for rule out coronary artery disease with the positive findings of 18 F-FDG-PET in case of systemic sarcoidosis. Int J Cardiol. 2014;172:e401–2.

    Article  PubMed  Google Scholar 

  51. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessment of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329–36. This is the first study to report the prognostic value of PET/CT in patients with CS and the relationship between magnitude of FDG uptake and patient outcomes.

    Article  PubMed  Google Scholar 

  52. Skali H, Schulman AR, Dorbala S. 18 F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep. 2013;15:352–63.

    Article  PubMed Central  Google Scholar 

  53. Lucignani G, Paganelli G, Bombardieri E. The use of standardized uptake values for assessing FDG uptake in oncology: a clinical perspective. Nucl Med Commun. 2004;25:651–6.

    Article  CAS  PubMed  Google Scholar 

  54. Tahara N, Tahara A, Nitta Y, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. J Am Coll Cardiol Imaging. 2010;3:1219–28.

    Article  Google Scholar 

  55. Bartlett ML, Bacharach SL, Voipio-Pulkki LM, et al. Artefactual inhomogeneities in myocardial PET and SPECT scans in normal subjects. J Nucl Med. 1995;36:188–95.

    CAS  PubMed  Google Scholar 

  56. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in diagnosis of cardiac sarcoidosis: a systemic review and meta-analysis including the Ontario experience. J Nucl Med. 2012;53:241–8. Meta-analysis of more than 300 patients in 7 studies that evaluated and compared diagnostic accuracy of FDG PET in CS.

    Article  CAS  PubMed  Google Scholar 

  57. Keijsers R, Verzijlbergen FJ, Rensing B, et al. Cardiac sarcoidosis: a challenge to measure disease activity. J Nucl Cardiol. 2008;15:595–8.

    Article  PubMed  Google Scholar 

  58. Manabe O, Oyama-Manabe N, Ohira H, et al. Multimodality evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2012;19:621–4.

    Article  PubMed  Google Scholar 

  59. Inohara T, Egashira T, Fujita J, et al. 18F-FDG-PET CT findings in a patient with early-phase cardiac sarcoidosis. Intern Med. 2013;52:2681.

  60. Nakamura S, Hashimoto Y, Nishi K, et al. High rate of cardiac sarcoidosis presenting with cutaneous plaque type sarcoidosis in 18 F-fluorodeoxyglucose positron emission tomography-computed tomography: a case series. J Med Case Rep. 2014;8:17.

    Article  PubMed Central  PubMed  Google Scholar 

  61. Koiwa H, Tsujino I, Ohira H, et al. Imaging of cardiac sarcoid lesions using fasting cardiac 18 F-fluorodeoxyglucose positron emission tomography: an autopsy case. Circulation. 2010;122:535–6.

    Article  PubMed  Google Scholar 

  62. Mc Ardle BA, Birnie DH, Klein R, et al. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by 18F-fluorodeoxyglucose positron emission tomography? Circ Cardiovasc Imaging. 2013;6:617–26. Important study that compared the intensity and location of FDG uptake with clinical presentation of CS, advanced atrioventricular block, and ventricular tachycardia.

    Article  PubMed  Google Scholar 

  63. Manabe O, Ohira H, Yoshinaga K, et al. Elevated 18F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis. Eur J Nucl Med Mol Imaging. 2013;40:1558–66. This study points out the relationship between FDG uptake in the interventricular septum and atrioventricular block in patients with CS.

    Article  CAS  PubMed  Google Scholar 

  64. Dubrey WS, Falk EH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis. 2010;52:336–46.

    Article  PubMed  Google Scholar 

  65. Gyorik S, Ceriani L, Menafoglio A, et al. 18 F-FDG PET scan as follow-up tool for sarcoidosis with symptomatic cardiac conduction disturbances requiring a pacemaker. Thorax. 2007;62:560.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  66. Khan SS, Lafemina M, Kroll C, et al. Cardiac sarcoidosis: 18FFDG-PET/CT as the most helpful tool in the decision making of medical management and assessment of response to treatment. J Pulm Respir Med. 2013;3:160. doi:10.4172/2161-105X.1000160.

    Google Scholar 

  67. Mc Ardle BA, Leung E, Ohira H, et al. The role of 18F-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol. 2013;20:297–306. Nice review with illustrative clinical cases pointing out the significance of FDG PET for diagnosis and management of CS.

    Article  CAS  PubMed  Google Scholar 

  68. Paz YE, Bokhari S. The role of F18-fluorodeoxyglucose positron emission tomography in identifying patients at high risk for lethal arrhythmias from cardiac sarcoidosis and the use of serial scanning to guide therapy. Int J Cardiovasc Imaging. 2014;30:431–8.

    Article  PubMed  Google Scholar 

  69. Osborne MT, Hulten EA, Singh A, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21:166–74. The first study to evaluate the relationship between left ventricular function and degree of FDG uptake in CS.

    Article  PubMed  Google Scholar 

  70. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States. A Delphi Study Chest. 2012;141:154–62.

    Article  CAS  Google Scholar 

  71. Chang JM, Lee HJ, Goo JM, et al. False positive and false negative FDG-PET scan in various thoracic diseases. Korean J Radiol. 2006;7:57–69.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatients testing. Chest. 2008;133:1426–35.

    Article  PubMed  Google Scholar 

  73. Isiguzo M, Brunken R, Techou P, et al. Metabolism-perfusion imaging to predict disease activity in cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:87–94.

    Google Scholar 

  74. Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. Am J Roentgenol. 2005;184:249–54.

    Article  Google Scholar 

  75. Ishimura S, Tsujino I, Sakaue S, et al. Combination of 18 F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22:234–5.

    Google Scholar 

  76. Schneider S, Batrice A, Rischpler C, et al. Utility of multimodal cardiac imaging with PET/MRI in cardiac sarcoidosis: implications for diagnosis, monitoring and treatment. Eur Heart J. 2014;35:312. doi:10.1093/eurheartj/eht335.

    Article  PubMed  Google Scholar 

  77. Evanchan JP, Crouse ED, Kalbfleisch SJ. Cardiac sarcoidosis: recent advances in diagnosis and treatment and an argument for the need for systemic multidisciplinary approach to management. J Innov Cardiac Rhythm Manage. 2013;4:1160–74.

    Google Scholar 

  78. Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing whole-body dual-modality 18 F-FDGPET/CT examinations. J Nucl Med. 2005;46:608–13.

    CAS  PubMed  Google Scholar 

  79. Nery PB, Mc Ardle BA, Redpath CJ, et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. PACE. 2014;37:364–74.

    Article  PubMed  Google Scholar 

  80. Hess S, Blomberg BA, Rakheja R, et al. A brief overview of novel approaches to FDG PET Imaging and quantification. Clin Transl Imaging. 2014. doi:10.1007/s40336-014-0062-2.

    Google Scholar 

Download references

Acknowledgments

The study is supported by the Serbian Ministry of Education and Science (grant No 175018).

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Dragana Sobic-Saranovic, Vera Artiko, and Vladimir Obradovic declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Faculty of Medicine, University of Belgrade, Belgrade, Serbia

    Dragana Sobic-Saranovic, Vera Artiko & Vladimir Obradovic

  2. Center of Nuclear Medicine, PET Center, Clinical Center of Serbia, Visegradska 26, 11000, Belgrade, Serbia

    Dragana Sobic-Saranovic, Vera Artiko & Vladimir Obradovic

Authors
  1. Dragana Sobic-Saranovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vera Artiko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vladimir Obradovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dragana Sobic-Saranovic.

Additional information

This article is part of the Topical Collection on Cardiac Nuclear Imaging

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sobic-Saranovic, D., Artiko, V. & Obradovic, V. PET/CT Imaging in Cardiac Sarcoidosis. Curr Cardiovasc Imaging Rep 8, 9305 (2015). https://doi.org/10.1007/s12410-014-9305-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s12410-014-9305-x

Keywords

Search

Navigation